Drug Profile
TBX 1400
Latest Information Update: 04 Sep 2023
Price :
$50
*
At a glance
- Originator Taiga Biotechnologies
- Class Stem cell therapies
- Mechanism of Action Immunostimulants; Stem cell modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Immunodeficiency disorders
Most Recent Events
- 04 Sep 2023 Discontinued - Preclinical for Immunodeficiency disorders in Israel (Parenteral)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Immunodeficiency-disorders in Israel (Parenteral)
- 13 Jun 2016 TBX 1400 receives Orphan Drug status for Immunodeficiency disorders (Severe combined immunodeficiency) in USA